Literature DB >> 16007214

Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways.

Qing Xu1, Jon Briggs, Sungman Park, Guilian Niu, Marcin Kortylewski, Shumin Zhang, Tanya Gritsko, James Turkson, Heidi Kay, Gregg L Semenza, Jin Q Cheng, Richard Jove, Hua Yu.   

Abstract

Vascular endothelial growth factor (VEGF) upregulation is induced by many receptor and intracellular oncogenic proteins commonly activated in cancer, rendering molecular targeting of VEGF expression a complex challenge. While VEGF inducers abound, only two major transcription activators have been identified for its promoter: hypoxia inducible factor-1 (HIF-1) and signal transducer and activator of transcription (Stat3). Both HIF-1 expression and Stat3 activity are upregulated in diverse cancers. Here, we provide evidence that Stat3 is required for both basal and growth signal-induced expression of HIF-1. Moreover, induction of VEGF by diverse oncogenic growth stimuli, including IL-6R, c-Src, Her2/Neu, is attenuated in cells without Stat3 signaling. We further demonstrate that Stat3 regulates expression of Akt, which is required for growth signal-induced HIF-1 upregulation. Targeting Stat3 with a small-molecule inhibitor blocks HIF-1 and VEGF expression in vitro and inhibits tumor growth and angiogenesis in vivo. Furthermore, tumor cells' in vivo angiogenic capacity induced by IL-6R, which simultaneously activates Jak/STAT and PI3K/Akt pathways, is abrogated when Stat3 is inhibited. Activation of Stat3 signaling by various growth signaling is prevalent in diverse cancers. Results presented here demonstrate that Stat3 is an effective target for inhibiting tumor VEGF expression and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007214     DOI: 10.1038/sj.onc.1208719

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  224 in total

1.  STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo.

Authors:  Aws Alshamsan; Samar Hamdy; Azita Haddadi; John Samuel; Ayman O S El-Kadi; Hasan Uludağ; Afsaneh Lavasanifar
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

2.  Nature versus nurture in glioblastoma: microenvironment and genetics can both drive mesenchymal transcriptional signature.

Authors:  Brent A Orr; Charles G Eberhart
Journal:  Am J Pathol       Date:  2012-03-23       Impact factor: 4.307

Review 3.  Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.

Authors:  Sumanta Kumar Pal; Marcin Kortylewski; Hua Yu; Robert A Figlin
Journal:  Mol Cancer Ther       Date:  2010-11-15       Impact factor: 6.261

4.  Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma.

Authors:  Makoto Adachi; Caixia Cui; Cristina T Dodge; Mihir K Bhayani; Stephen Y Lai
Journal:  Oral Oncol       Date:  2012-07-06       Impact factor: 5.337

Review 5.  Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Aspects Med       Date:  2013-08-29

6.  JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.

Authors:  Sven Schwemmers; Britta Will; Cornelius F Waller; Khadija Abdulkarim; Peter Johansson; Björn Andreasson; Heike L Pahl
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

7.  Curcumin inhibits human non-small cell lung cancer xenografts by targeting STAT3 pathway.

Authors:  Xiaofang Xu; Yuping Zhu
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 8.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

9.  STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma.

Authors:  Qu Zhang; Chi Zhang; Jia He; Qing Guo; Desheng Hu; Xi Yang; Jinfeng Wang; Yahui Kang; Ruifang She; Zhongming Wang; Defan Li; Guanhong Huang; Zhaoming Ma; Weidong Mao; Xiaoyi Zhou; Chuangying Xiao; Xinchen Sun; Jianxin Ma
Journal:  Tumour Biol       Date:  2014-12-10

10.  Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro.

Authors:  Weidong Li; Shakir M Saud; Matthew R Young; Nancy H Colburn; Baojin Hua
Journal:  Mol Cell Biochem       Date:  2015-04-26       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.